Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-3. (Cancelled).

4. (Presently Amended) ~~The~~ A base for a percutaneously absorbing preparation ~~according to claims 1 to 3~~, wherein styrene-isoprene-styrene block copolymer and/or polyisobutylene, softener and tackifier are essential components and hexylene glycol and 1-menthol are sorbefacients as the components of the base.

5. (Presently Amended) The base for a percutaneously absorbing preparation according to ~~claims 2 to~~claim 4, wherein 10-40% by weight of styrene-isoprene-styrene block copolymer, 2-10% by weight of polyisobutylene, 10-60% by weight of softener and 20-60% by weight of tackifier are essential components and 1-10% by weight of hexylene glycol and 0.1-7% by weight of 1-menthol are compounded therewith as the components of the base.

6. (Presently Amended) A percutaneously absorbing preparation ~~according to claims 4 to 5,~~ wherein a pharmaceutical agent is contained as an effective ingredient in the base for a percutaneously absorbing preparation mentioned in claims 4 to 5.

7. (Presently Amended) The percutaneously absorbing preparation according to ~~claims 4~~ toclaim 6, wherein the pharmaceutical agent is follicular hormone and/or luteinizing hormone.

8. (Original) The percutaneously absorbing preparation according to claim7,wherein the

follicular hormone is estradiol or a derivative thereof and its compounding amount if 0.1-5% by weight.

9. (Original) The percutaneously absorbing preparation according to claim 7, wherein the luteinizing hormone is norethisterone, norethisterone acetate or a derivative thereof and its compounding amount is 0.5-10% by weight.